ALLGF - Week In Review: Biotheus Acquires China Rights To 3 Bi-Specifics In $142 Million Deal
Deals and Financings
Biotheus, a China biopharma based in Zhuhai, Guangdong, announced a $142 million agreement to in-license greater China rights for a TNFR antibody developed by Alligator Bioscience of Stockholm (ALLGF). Formed in 2018, Biotheus will have rights for up to three bi-specific candidates based on the antibody. The agreement, which specifies a $1 million upfront payment, will include a $90 million option for Biotheus to acquire global rights to the candidates. Biotheus is developing a pipeline of me-better/novel candidates focused on immuno-oncology and metabolic disease.
Yaoyanshe, a Shanghai online AI-based CRO/CMO, raised $42